Merosin-deficient congenital muscular dystrophy type 1A: A case report

Banker BQ and Engel AG: Basic reactions of muscle. Myology: Basic and Clinical. Engel AG and Franzini-Armstrong C: 3rd edition. McGraw-Hill; New York, NY: pp. 691–748. 2004

Tomé FM, Evangelista T, Leclerc A, et al: Congenital muscular dystrophy with merosin deficiency. C R Acad Sci III. 317:351–377. 1994.

Xiong H, Yao S, Yuan Y, et al: Diagnosis of congenital muscular dystrophy and clinical significance of merosin expression. Zhonghua Er Ke Za Zhi. 44:918–923. 2006.(In Chinese).

Paternostro-Sluga T, Grim-Stieger M, Posch M, Schuhfried O, Vacariu G, Mittermaier C, Bittner C and Fialka-Moser V: Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. J Rehabil Med. 40:665–671. 2008. View Article : Google Scholar : PubMed/NCBI

Voit T and Tomé FS: The congenital muscular dystrophies. Myology: Basic and Clinical. Engel AG and Franzini-Armstrong C: 3rd edition. McGraw-Hill; New York, NY: pp. 1203–1238. 2004

Mostacciuolo ML, Miorin M, Martinello F, et al: Genetic epidemiology of congenital muscular dystrophy in a sample from north-east Italy. Hum Genet. 97:277–279. 1996. View Article : Google Scholar : PubMed/NCBI

Jones KJ, Morgan G, Johnston H, et al: The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review. J Med Genet. 38:649–657. 2001. View Article : Google Scholar : PubMed/NCBI

Sparks S, Quijano-Roy S, Harper A, et al: Congenital Muscular Dystrophy Overview. GeneReviews™ [Internet]. Pagon RA, Adam MP, Bird TD, et al: University of Seattle; Seattle, WA: 2001, http://www.ncbi.nlm.nih.gov/books/NBK1291/uri.

Di Muzio A, De Angelis MV, Di Fulvio P, et al: Dysmyelinating sensory-motor neuropathy in merosin-deficient congenital muscular dystrophy. Muscle Nerve. 27:500–506. 2003.PubMed/NCBI

Philpot J, Sewry C, Pennock J and Dubowitz V: Clinical phenotype in congenital muscular dystrophy: correlation with expression of merosin in skeletal muscle. Neuromusc Disord. 5:301–305. 1995. View Article : Google Scholar : PubMed/NCBI

Sijens PE, Fock JM, Meiners LC, et al: MR spectroscopy and diffusion tensor imaging of the brain in congenital muscular dystrophy with merosin deficiency: metabolite level decreases, fractional anisotropy decreases, and apparent diffusion coefficient increases in the white matter. Brain Dev. 29:317–321. 2007. View Article : Google Scholar

Brockmann K, Dechent P, Bönnemann C, et al: Quantitative proton MRS of cerebral metabolites in laminin alpha2 chain deficiency. Brain Dev. 29:357–364. 2007. View Article : Google Scholar : PubMed/NCBI

Sunada Y, Edgar TS, Lotz BP, et al: Merosin-negative congenital muscular dystrophy associated with extensive brain abnormalities. Neurology. 45:2084–2089. 1995. View Article : Google Scholar : PubMed/NCBI

Fardeau M, Tomé FM, Helbling-Leclerc A, et al: Congenital muscular dystrophy with merosin deficiency: clinical, histopathological, immunocytochemical and genetic analysis. Rev Neurol (Paris). 52:11–19. 1996.(In French).

Helbling-Leclerc A, Zhang X, Topaloglu H, et al: Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet. 11:216–218. 1995. View Article : Google Scholar : PubMed/NCBI

Burgeson RE, Chiquet M, Deutzmann R, et al: A new nomenclature for the laminins. Matrix Biol. 14:209–211. 1994. View Article : Google Scholar : PubMed/NCBI

Di Blasi C, Piga D, Brioschi P, et al: LAMA2 gene analysis in congenital muscular dystrophy: new mutations, prenatal diagnosis, and founder effect. Arch Neurol. 62:1582–1586. 2005.PubMed/NCBI